about
Tuberculin skin test result and risk of death among persons with active TBDevelopment of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studiesSputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.How we determined the most reliable solid medium for studying treatment of tuberculosis.Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis.Association between tuberculin skin test result and clinical presentation of tuberculosis diseaseVaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection.Comparative Yield of Different Diagnostic Tests for Tuberculosis among People Living with HIV in Western Kenya.Performance of Clinical Screening Algorithms for Tuberculosis Intensified Case Finding among People Living with HIV in Western Kenya.Tuberculosis Caused by Mycobacterium africanum, United States, 2004-2013.Mind the gap: TB trends in the USA and the UK, 2000-2011Seasonality of tuberculosis in the United States, 1993-2008.Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program.Assessing the effect of decentralisation of laboratory diagnosis for drug-resistant tuberculosis in Kenya.Factors associated with recurrent tuberculosis more than 12 months after treatment completion.Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.The utility of stool cultures for diagnosing tuberculosis in people living with the human immunodeficiency virus.Improving participant understanding of informed consent in an HIV-prevention clinical trial: a comparison of methods.What is the most reliable solid culture medium for tuberculosis treatment trials?Cancer incidence in women with or at risk for HIV.Symptom screen for identification of highly infectious tuberculosis in people living with HIV in Southeast Asia.IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis.Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy.Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology.Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women.Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus.Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity.Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.A critical history of individual and collective ethics in the lineage of Lellouch and Schwartz.Accuracy of Papanicolaou test among HIV-infected women.Ethical justification for conducting public health surveillance without patient consentLessons from a randomised clinical trial for multidrug-resistant tuberculosisRisk Factors for Cesarean Delivery Among Puerto Rican WomenEffect of HIV Infection on Atypical Squamous Cells of Undetermined SignificanceHIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survivalLymphocyte Homeostasis in HIV-Infected Northern Thais
P50
Q28535009-DBB36F75-C733-4D72-8089-2DB0CE0D848BQ28743478-C4381213-BB35-4C75-B7FD-E6D1914C2588Q30901894-0501C7E3-9242-4D7F-A46E-1710C6B3CA8DQ33735589-D321288D-397C-4A19-8DFD-E18A9058FCFDQ33746114-F3AF4AE7-1F0D-43BF-8B3D-7865ADD780E0Q33805377-3EF99B69-558E-4404-B707-325BED81BB58Q34346977-24E47B62-A0E0-4495-A3F0-695967504222Q35008119-2E5CEAB4-6708-4CA7-802F-8E8893532E69Q35614592-AAC15EF7-CFDE-4415-BBF0-6AA39468FA2FQ35972660-D655D455-3EC4-4094-AFEF-FEC006F5D172Q36218341-25338F14-9FD8-451A-9C62-D5BF807E5A5AQ36617008-30AB7BAE-9525-4A33-BDEB-6F7FA7DADFFAQ36689518-F847906A-699E-41EE-AD3A-88F466789ECCQ36902743-72D941DF-1208-4582-9BF5-B6896750B18FQ36905756-63738D66-D0A0-4A3D-B866-91C76035B064Q37243872-E092C413-0170-4702-B1F1-7DDC7B4B03F3Q37371468-01B0D611-D85A-4A33-A9AB-BE5B5F418414Q37434341-B62C5CB6-A9F9-4BF0-86D6-E0A3BD31D522Q37495457-8B451157-D1E3-4E3F-9729-EC12CEDB5BB0Q37582260-F363E84C-0BDA-4034-92A4-23BA52708724Q38862764-38BFD6B0-8F8B-462F-A500-687576A0B1A6Q39587834-419331F2-8B68-4B60-9CF6-458ACE9048ACQ40290869-FDD542A2-6A42-4053-837A-0048C6EDEACFQ40600140-6AED95D9-5B9C-4CCA-8377-C13804C5E138Q42214113-D550D3D8-19F3-4923-A631-A1EC73C0C7F9Q43597185-70D3C2B3-2223-4D40-9A50-E595930976E9Q44833599-79AC2CE0-3BB6-48DD-AC55-D89A232AD754Q44943954-4AEC8C8A-EFFC-497D-ABD5-65274F638243Q45146536-DEFC37D8-0BF6-416F-B7FE-38E734D7F4C3Q45417212-95B35212-ED49-4EFA-8147-27AC93A9A15DQ45728748-99BA3E68-3192-45C1-939F-043D8764E3F5Q46029821-57C95F30-E53F-47FD-AA0B-4C99A695154BQ50953149-8DE7B667-4E47-4CC9-B2E6-73B46F275829Q51955650-1E5A0F0A-C4A9-4119-8F59-9B11D81A97B1Q56775442-2BEC78E8-B443-4306-9DC5-1D4EC6067BCAQ56927295-A33E06DE-BE4D-445C-A21B-1FF5CF42E72AQ57556240-1B89592C-C965-4FF5-A2DE-3C6055CE3FFBQ57556245-81890B60-F2CC-4786-A179-3C972DCE78A6Q57556256-50444F85-72EE-41A4-A7D9-7254477637B6Q57556261-DE0F8A49-DC4E-419A-A164-05478C2DB574
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Charles M. Heilig
@ast
Charles M. Heilig
@en
Charles M. Heilig
@es
Charles M. Heilig
@nl
Charles M. Heilig
@sl
type
label
Charles M. Heilig
@ast
Charles M. Heilig
@en
Charles M. Heilig
@es
Charles M. Heilig
@nl
Charles M. Heilig
@sl
prefLabel
Charles M. Heilig
@ast
Charles M. Heilig
@en
Charles M. Heilig
@es
Charles M. Heilig
@nl
Charles M. Heilig
@sl
P106
P1153
7003299191
P21
P31
P496
0000-0003-1075-1310
P569
2000-01-01T00:00:00Z